> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Kazia Touts Glioblastoma Drug Trial Results
- URL: https://www.fdaweb.com/kazia-touts-glioblastoma-drug-trial-results/
- Published: 2024-07-10T12:00:00.000Z
- Updated: 2026-09-14T14:35:05.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157317

Kazia Therapeutics says a Phase 2/3 trial evaluating its paxalisib versus standard of care for patients with glioblastoma demonstrated the drug’s effectiveness in extending overall survival. A company [statement](https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-phase-iiiii-clinical-trial-results-for-paxalisib-in-glioblastoma-302193414.html?ref=fdaweb.com) says the trial showed a 3.8-month improvement in overall survival for newly diagnosed unmethylated patients with glioblastoma compared to the current standard of care.

The company says it will request a meeting with FDA to discuss the results and determine if a potential path to accelerated approval is appropriate. Paxalisib has already been granted FDA orphan drug and fast-track designations for glioblastoma in unmethylated MGMT promoter status patients following radiation plus temozolomide (Merck’s Temodar).